Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B - PubMed
3 hours ago
- #Clinical Trial
- #Transthyretin Amyloidosis
- #Heart Failure
- Vutrisiran reduced the risk of a composite of all-cause mortality and recurrent cardiovascular events in East Asian patients with ATTR-CM compared to placebo (HR: 0.20).
- Vutrisiran preserved functional capacity and quality of life, showing attenuated declines in 6-minute walk test distance and KCCQ-OS scores, with more patients maintaining or improving NYHA functional class.
- Smaller increases in NT-proBNP and troponin I levels were observed with vutrisiran versus placebo, indicating potential cardiac benefit.
- Safety of vutrisiran in East Asian patients was consistent with the overall HELIOS-B population, despite lower baseline tafamidis use in this subgroup.